A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
|Articles|October 1, 1997
The American Journal of Managed Care
- October 1997
- Volume 3
- Issue 10
The Abilities of Primary Care Physicians in Dermatology: Implications for Quality of Care
Author(s)Daniel G. Federman, MD, Robert S. Kirsner, MD
Advertisement
Articles in this issue
almost 29 years ago
Using Evidence-Based Techniques to Modify Anemia Screening Practicealmost 29 years ago
Migraine: A Problem for Employers and Managed Care Plansalmost 29 years ago
Travel Medicine: Considerations for the Primary Care PhysicianAdvertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
3
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
4
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
5